Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 May 11;2006(4):93253. doi: 10.1155/MI/2006/93253

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006 Peng Lv et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Immunohistochemical staining for VCAM-1 in rat liver. N represented the normal control group; M represented the model group; L represented the group treated with low dose of thalidomide; H represented the group treated with high dose of thalidomide. (a) Positive VCAM-1 cells were mainly distributed at the fibrosepta band, area of necrosis, and inflammatory cell infiltration in hepatic lobules (M, L, and H) (original magnification N, M, L, H, ×400, immunohistochemical staining). (b) Comparison of the expression of VCAM-1 using immunohistochemical analysis. ^aP < .01 versus normal control group; ^bP < .01 versus model group; ^cP < .01 group treated with high dose of thalidomide versus group treated with low dose of thalidomide.

Immunohistochemical staining for VCAM-1 in rat liver. N represented the normal control group; M represented the model group; L represented the group treated with low dose of thalidomide; H represented the group treated with high dose of thalidomide. (a) Positive VCAM-1 cells were mainly distributed at the fibrosepta band, area of necrosis, and inflammatory cell infiltration in hepatic lobules (M, L, and H) (original magnification N, M, L, H, ×400, immunohistochemical staining). (b) Comparison of the expression of VCAM-1 using immunohistochemical analysis. ^aP < .01 versus normal control group; ^bP < .01 versus model group; ^cP < .01 group treated with high dose of thalidomide versus group treated with low dose of thalidomide.